Skip to content

Study on the regularity of tumor autoantibodies caused by Ruji Formula in the treatment of breast cancer

Study on the regularity of tumor autoantibodies caused by Ruji Formula in the treatment of breast cancer

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200063988
Enrollment
Unknown
Registered
2022-09-22
Start date
2022-09-23
Completion date
Unknown
Last updated
2023-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer

Interventions

Treatment group:Standardized treatment + Ruji Formula
Control group:None

Sponsors

Foshan Hospital of TCM
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Treatment group: (1) Voluntary signing of informed consent; (2) Aged 18-80 years; (3) Women; (4) Patients with breast cancer diagnosed by pathology according to the ''Breast Cancer Diagnosis and Treatment Guidelines 2020'' designated by the Guidelines Working Committee of the Chinese Society of Clinical Oncology (CSCO); (5) Patients who completed postoperative adjuvant therapy; Good follow-up compliance; (6) Survival expectancy >=3 months; Good follow-up compliance; (7) Patients who need to receive milk prescription treatment according to the judgment of treating doctors. 2. Control group: (1) Voluntary signing of informed consent; (2) Aged 18-80 years; (3) Women; (4) Healthy people with no malignant tumor found by physical examination in recent 3 months.

Exclusion criteria

Exclusion criteria: 1. Complicated with other malignant tumors; 2. Participating in or about to participate in other clinical trials; 3. It is judged by the researcher that it is not suitable to participate in this study; 4. Pregnancy.

Design outcomes

Primary

MeasureTime frame
Tumor autoantibody;

Secondary

MeasureTime frame
Blood routine;Liver and kidney function;Urine examination;Fecal examination;Tumor markers;Electrocardiogram;

Countries

China

Contacts

Public ContactTian Huaqin

Foshan Hospital of TCM

13929969262@139.com+86 13929969262

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026